Remove Bipolar disorder Remove Reference Remove Sleep and mental health
article thumbnail

What Is a Sleep Disorder? A Harmful Dysfunction Analysis

Psychiatric Times

A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. SHOW MORE What is a sleep disorder?

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. References 1. points (effect size 0.61) in study 501 and 4.5 points (effect size 0.56) vs placebo in study 502. Supplemental new drug application submitted to U.S.

article thumbnail

How Do Psychiatry Residents Learn Psychopharmacology?

Psychiatric Times

References 1. Dr Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. He is currently a professor at the University of California, San Diego, and serves as Honorary Fellow in psychiatry department at the University of Cambridge. Stahl SM, Davis RL.

Education 123